Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial

Lancet

Volumn 353, Issue 9167, 1999, Pages 1819-1823

  Vestbo, Jørgen ^a,e   Sørensen, Torben ^a   Lange, Peter ^b   Brix, Anders ^c   Tone, Piero ^d   Viskum, Kaj ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d ASTRA Danmark A/S   (Denmark)

^e University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CORTICOSTEROID; PLACEBO; PREDNISOLONE; TERBUTALINE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INHALER; LONG TERM CARE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; VIRUS INFECTION; VITAL CAPACITY;

EID: 0033614639     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)10019-3     Document Type: Article

References (31)

1. Jackevicius CA, Chapman KR. Prevalence of inhaled corticosteroid use among patients with chronic obstructive pulmonary disease: a survey. Ann Pharmacother 1997; 31: 160-64.
2. Postma DS, Steenhuis EJ, van der Weele LT, Sluiter HJ. Severe chronic airflow obstruction: can corticosteroids slow down progression? EurJRespir Dis 1985; 67: 56-64.
3. Postma DS, Peters I, Steenhuis EJ, Sluiter HJ. Moderately severe chronic airflow obstruction: can corticosteroids slow down progression? EUT RespirJ 1 988; 1: 22-26.
4. Kerstjens HAM, Brand PLP, Hughes MD, et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. NEnglJMed 1992; 327: 1413-19.
5. RenkemaTEJ, Scheuten JP, KoeterGH. Postma DS. Effects of longterm treatment with corticosteroids in COPD. Chest 1996; 109: 1156-62.
6. Derenne JP. Effects of high-dose inhaled beclomethasome on the rate of decline in FEVj in patients with chronic obstructive pulmonary disease: results of a 2 year prospective multicentre study. Am J Respir Grit Care Med 1995; 151:A463 (abstr).
7. Burge PS. A double blind randomised placebo controlled two year study of inhaled beclomethasone dipropionate in patients with non-asthmatic COPD. Eur Respir J\ 997; 10 (suppl 25): 391S (abstr).
8. van Grunsven PM, van Schayck CP, Derenne JP, et al. Long-term effects of inhaled cortico steroid s in chronic obstructive pulmonary disease: a me ta-analysis. Thorax 1999; 54: 7-14.
9. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, EfthimiouJ, on behalf of the International COPD Study Group. Multicentre randomised placebo-controlled trial in inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351: 773-80.
10. Appleyard M, Hansen AT, Schnohr P, Jensen G, Nyboe J. The Copenhagen City Heart Study: a book of tables with data from the first examination (1976-78) and a 5-year follow-up (1981-83). Scand J Soc Med 1989; 170 (suppl 41): 1-160.
11. Lange P. Development and prognosis of chronic obstructive pulmonary disease with special reference to the role of tobacco smoking: an epidemiologic study. DanMedBuU 1992; 39: 30-48.
12. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault J-C. Long volumes and forced ventilatory flows. Eur Respir J 1993; 6 (suppl 16): 5J-0.
13. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963-74.
14. Agresti A. A survey of models for repeated ordered categorical response data. Stat Med 1989:, S: 1209-24.
15. Pauwels RA, Lofdahl CG, Pride NB, Postma DS, Laitinen LA, Ohlsson SV. European Respiratory Society study on chronic obstructive pulmonary disease (Euroscop): hypothesis and design. Eur Respir J 1992; 5:1254-61.
16. Bürge PS, Calverley PMA, Daniels JE. The acute effect of oral prednisolone in patients with COPD in the ISOLDE trial: responders and non-responders? Am J Respir Crit Care Med 1996; 153:A126 (abstr).
17. Burrows B, Knudson RJ, Camilli AE, Lyle SK, Lebowitz MD. The "horse racing effect" and predicting decline in forced expiratory volume in one second from screening spirometry. Am Rev Respir Dis 1987;135:788-93.
18. Vestbo J, Prescott E, Lange P, Copenhagen City Heart Study Group. Association of chronic mucus hypersécrétion with FEV\ decline and COPD morbidity. Am J Respir Grit Care Med 1996; 153: 1530-35.
19. Callahan CM, Dittus RS, Katz BP. Oral cortico steroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 1991; 114:216-23.
20. Tashkin DP, Altose MD, Connett JE, Kanner RE, Lee WW, Wise RA, for the Lung Health Study Research Group. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 1802-11.
21. Leynaert B, Bousquet J, Henry C, Liard R, Neukirch F. Is bronchial hyperresponsiveness more frequent in women than in men? A population-based study. Am J Respir Crit Care Med 1997; 156: 1413-20.
22. Haahtela T, Jarvinen M, Kava T, et al. Comparison of a beta2-agonist, terbutaline, with an inhaled cortices ter oid, budesonide, in newly detected asthma. NEnglJMed 1991 ; 325: 388-92.
23. Lenfant C, ed. Global strategy for asthma management and prevention. NHBLI/WHO workshop report [NDH Publication No. 95-3659]. Bethesda: National Heart, Lung, and Blood Institute, 1995.
24. Lacoste JY, Bousquet J, Chanez P, et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol 1 993; 92: 537J8.
25. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med 1997; 155: 449-53.
26. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155:542-48.
27. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV,: the Lung Health Study. JAMA 1994; 272: 1497-505.
28. Orie NGM, Sluiter HJ, de Vries K, Tammeling GJ, Witkop J. The host factor in bronchitis. In: Orie NGM, Sluiter HJ, eds. Bronchitis: an international symposium. Assen, Netherlands: Royal van Gorcum, 1961.
29. Vestbo J, Prescott E. Update on the "Dutch hypothesis" for chronic respiratory disease. Thorax 1998; 53 (suppl 2): S15-19.
30. Rijcken B, Weiss ST. Longitudinal analyses of airway responsive ness and pulmonary function decline. Am J Respir Crit Care Med 1996; 154: S246-49.
31. Xu X, Rijcken B, Scheuten JP, Weiss ST. Airways responsiveness and development and remission of chronic respiratory symptoms in adults. Lancet 1997; 350: 1431-34.